Tag: Novo Nordisk

Novo Nordisk’s Operating Profit Increased by 12%

novo nordisk
Novo Nordisk's operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019. Sales increased by 9% in Danish kroner and by 5% at CER...

Purdue Sold Plant to Novo Nordisk

Purdue has sold its Treyburn, North Carolina, plant to Novo Nordisk for an undisclosed sum, according to an announcement Purdue CEO Craig Landau sent to the plant’s employees. In support of our busin...

Novo Nordisk and e-Therapeutics Extended Drug Discovery Collaboration

novo nordisk
Novo Nordisk and e-Therapeutics have opted to extend their drug discovery collaboration launched last December in Type 2 diabetes to incorporate a new approach to genomic data. The amended research...

CHMP Recommends Treatment for Paediatric Type 2 Diabetes

EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with typ...

EU Granted Marketing Authorisation for Novo Nordisk’s Esperoct

Novo Nordisk
Novo Nordisk announced that the European Commission has granted marketing authorisation for Esperoct®for the treatment of adolescents (≥12 years of age) and adults with haemophilia A. The authorisatio...

FDA Approved Novo Nordisk’s Victoza

The U.S. Food and Drug Administration approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approve...

Novo Nordisk Announce Q1 Financial Results

Novo Nordisk
Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes. With Novo’s traditional ...

Support of Haemophilia Parients in Azerbaijan

Haemophilia patients are covered by Azerbaijan government not only through providing free of charge medicines but also being supported to have healthy and high quality of life. This topic was highl...

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration

Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (N...

Teva to Launch Generis of Novo Nordisk Non-Insulin Med

Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza® (liraglutide). Consequently...

Novo Nordisk Submitted Label Updates for its Insulin Aspart

Novo Nordisk announced that it has submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (fast-acting insulin aspart), seeking approva...

Abbott and Novo Nordisk Team Up

Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with FreeStyle Libre portfolio of products. Abbott and Novo Nordi...

Abbott and Novo Nordisk in Partnership

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools...

FDA Approved Haemophilia A of Novo Nordisk

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A. ESPER...

Novo Nordisk Expects Fast-Track Review for New Semaglutide

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US. The FDA grants ...

Drug Giants Should Explain High Prices on Insulin

Sanofi, Eli Lilly and Novo Nordisk have been sent letters by US lawmakers requesting information on the increased costs of insulin in recent years and the companies’ profit from sales of these product...